Novartis | NVS - Biaya Penjualan





Biaya Penjualan Perubahan Tanggal
AbbVie USD 4.22B 329M 2026-03
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Bausch Health Companies USD 979M 55M 2026-03
Biogen USD 797.5M 302M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Canopy Growth CAD 62.98M 9.91M 2026-03
Corcept Therapeutics USD 2.88M 338K 2026-03
Drreddys Laboratories INR 32.13B 8.34B 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
Glaxosmithkline GBP 1.88B 1.6B 2026-03
J&J USD 8B 67M 2026-06
Merck USD 2.94B 380M 2026-03
Novartis USD 3.46B 83M 2026-03
Novartis USD 3.46B 83M 2026-03
Pacira USD 50.74M 3.89M 2026-03
Perrigo USD 643.7M 103.7M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Phibro Animal Health USD 240.42M 2.58M 2025-12
Prestige Brands USD 140.76M 9.53M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 3.67B 621M 2026-03
Sanofi EUR 3.14B 618M 2026-03
Supernus Pharmaceuticals USD 49.04M 1.5M 2026-03
Zoetis USD 672M 71M 2026-03